10x Genomics, Inc. logo

10x Genomics, Inc.

TXG

NASDAQHealthcareMedical - Healthcare Information Services

Latest quote

$65.11

+$1.25 · +1.96%

Aug 21, 3:55 PM ET

TXG company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

66

Undervalued

Momentum

72

Gaining

Sentiment

45

Mixed

Risk resilience

52

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Serge Saxonov
Listed since
Sep 12, 2019
Employees
1,178

Market position

Volume
3.25M
1.04× average
Average volume
3.11M
Average daily volume
Market cap
8.27B USD
Beta
2.04
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends98%47%-5%-56%Gross margin, FY2021: 84.89%Gross margin, FY2022: 76.69%Gross margin, FY2023: 66.15%Gross margin, FY2024: 67.86%Gross margin, FY2025: 69.05%Operating margin, FY2021: -10.79%Operating margin, FY2022: -32.52%Operating margin, FY2023: -42.88%Operating margin, FY2024: -31.85%Operating margin, FY2025: -17.25%Net margin, FY2021: -11.87%Net margin, FY2022: -32.15%Net margin, FY2023: -41.23%Net margin, FY2024: -29.90%Net margin, FY2025: -6.77%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 84.89%. Gross margin FY2022 76.69%. Gross margin FY2023 66.15%. Gross margin FY2024 67.86%. Gross margin FY2025 69.05%. Operating margin FY2021 -10.79%. Operating margin FY2022 -32.52%. Operating margin FY2023 -42.88%. Operating margin FY2024 -31.85%. Operating margin FY2025 -17.25%. Net margin FY2021 -11.87%. Net margin FY2022 -32.15%. Net margin FY2023 -41.23%. Net margin FY2024 -29.90%. Net margin FY2025 -6.77%.

Income trends

Revenue

642.82M USD+5.25%

Operating income

−110.89M USD+43.01%

Net income

−43.54M USD+76.16%
Income trends across reported periods733.64M USD370.38M USD7.12M USD−356.14M USDRevenue, FY2021: 490.49M USDRevenue, FY2022: 516.41M USDRevenue, FY2023: 618.73M USDRevenue, FY2024: 610.79M USDRevenue, FY2025: 642.82M USDOperating income, FY2021: −52.91M USDOperating income, FY2022: −167.94M USDOperating income, FY2023: −265.33M USDOperating income, FY2024: −194.56M USDOperating income, FY2025: −110.89M USDNet income, FY2021: −58.22M USDNet income, FY2022: −166M USDNet income, FY2023: −255.1M USDNet income, FY2024: −182.63M USDNet income, FY2025: −43.54M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 490.49M USD. Revenue FY2022 516.41M USD. Revenue FY2023 618.73M USD. Revenue FY2024 610.79M USD. Revenue FY2025 642.82M USD. Operating income FY2021 −52.91M USD. Operating income FY2022 −167.94M USD. Operating income FY2023 −265.33M USD. Operating income FY2024 −194.56M USD. Operating income FY2025 −110.89M USD. Net income FY2021 −58.22M USD. Net income FY2022 −166M USD. Net income FY2023 −255.1M USD. Net income FY2024 −182.63M USD. Net income FY2025 −43.54M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue642.82M USD610.79M USD618.73M USD516.41M USD490.49M USD
Cost of goods sold198.94M USD196.3M USD209.41M USD120.39M USD74.09M USD
Gross profit443.88M USD414.48M USD409.31M USD396.02M USD416.4M USD
Research and development238.63M USD264.7M USD270.33M USD265.67M USD211.75M USD
Selling, general, and administrative316.13M USD344.34M USD343.33M USD298.3M USD257.56M USD
Operating expenses554.77M USD609.04M USD674.64M USD563.97M USD469.31M USD
Interest income20.05M USD18.45M USD16.91M USD6.65M USD206K USD
Interest expense4K USD33K USD476K USD866K USD
Depreciation and amortization43.82M USD43.71M USD43.62M USD33.01M USD28.25M USD
Operating income−110.89M USD−194.56M USD−265.33M USD−167.94M USD−52.91M USD
Net income−43.54M USD−182.63M USD−255.1M USD−166M USD−58.22M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+9.85%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.24 · Beat by 42.41%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.340.06-0.23-0.51Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 12, 2025: actual -0.4, estimate -0.29, surprise -37.93%, Miss. Q2 2025, reported May 8, 2025: actual -0.36, estimate -0.45, surprise +20.00%, Beat. Q3 2025, reported Aug 7, 2025: actual 0.28, estimate -0.35, surprise +180.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.22, estimate -0.07, surprise -214.29%, Miss. Q1 2026, reported Feb 12, 2026: actual -0.13, estimate -0.19, surprise +31.58%, Beat. Q2 2026, reported May 7, 2026: actual -0.1, estimate -0.29, surprise +65.52%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.14, estimate -0.243, surprise +42.41%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates179.82M164.08M148.34M132.6MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 12, 2025: actual 165.02M USD, estimate 164.98M USD, surprise +0.02%, Beat. Q2 2025, reported May 8, 2025: actual 154.88M USD, estimate 145.27M USD, surprise +6.62%, Beat. Q3 2025, reported Aug 7, 2025: actual 172.91M USD, estimate 139.51M USD, surprise +23.94%, Beat. Q4 2025, reported Nov 6, 2025: actual 149M USD, estimate 142.5M USD, surprise +4.56%, Beat. Q1 2026, reported Feb 12, 2026: actual 166.03M USD, estimate 159.65M USD, surprise +3.99%, Beat. Q2 2026, reported May 7, 2026: actual 150.84M USD, estimate 146.41M USD, surprise +3.03%, Beat. Q3 2026, reported Aug 6, 2026: actual 151.04M USD, estimate 146.67M USD, surprise +2.97%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 147.21M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

22 ratings
Strong buy00%
Buy1045%
Hold1150%
Sell15%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Jul 17, 2006

1:2

TXG peers

ETFs holding TXG

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research TXG

research.disclaimer